Focus on Asthma Care

Back to articles

Improving adherence is the key to success with asthma step-up therapy

August 19, 2013
  • Advising on this article:
  • Devra K. Dang

KEY POINT

In patients with asthma, use of an inhaled corticosteroid (ICS) plus a long-acting beta agonist (LABA) was associated with better adherence and improved asthma outcomes as compared to therapy with an ICS plus a leukotriene receptor antagonist (LTRA) over a 2-year period.

SOURCES

Sadatsafavi M et al. Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthmatic patients: a population-based study. J Allerg Clin Immunol. 2013;132:63–9.

O’Byrne PM. Asthma in the real world [editorial]. J Allerg Clin Immunol. 2013;132:70–1.

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.